Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Rheumatology
ASCO Journal Club
Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology
Questions discussed in this category
Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?
1 Answer available
Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?
1 Answer available
Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?
1 Answer available
5996
5995
5994
Papers discussed in this category
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
J Immunother Cancer, 2019 Aug 22
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.
Journal for immunotherapy of cancer, 2017-11-21
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Cancer management and research, 2017
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
Related Topics in Rheumatology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers